%0 Journal Article %A Patricia Sobradillo %A Antonia Fuster %A Pedro Jorge Marcos %A Ángel Ortega %A Cruz González %A Myriam Aburto %A Juan Luis Rodríguez %A Bernardino Alcázar %A Myriam Calle %A Luis Puente %T Use of beta-blockers in COPD patients with heart-disease. BBEPOC study %D 2013 %J European Respiratory Journal %P 3296 %V 42 %N Suppl 57 %X There is strong evidence showing increased survival with beta-blockers (BB) treatment in patients with chronic heart failure and after acute myocardial infarction. There is high evidence showing the safety of cardioselective BB in COPD. AIMS: 1) To determine the frequency of use of BB COPD patients in whom BB are indicated because of an underlying heart disease 2) To determine whether the use of BB decreases the risk of more than 2 exacerbations in such patients. METHODS: Observational multicenter study. Indication for BB: ischemic heart disease or heart failure with LVEF <40%. RESULTS: 186 COPD patients and 112 non-COPD patients. COPD patients were younger (701SEM years vs 73±1yr,p= 0.01) and female proportion lower (6±1% women vs. 26±1%, p 0.001). The use of BB was significantly higher in patients without COPD 99% (95%CI 96%-100%) than in those with COPD 61% (53%-67%), p<001. Within the COPD group, those prescribed with BB were younger (71±1 yr vs 73±1yr, p=0.01) had higher FEV1 (56±1.5% vs 51±2.3%,p<0.001) than those who were not on BB. The percentage of patients with ≥2 exacerbations was higher in the COPD without BB (29±5% vs 13±3, p=0.026). The OR of exacerbations in COPD not using BB compared with those using BB was 2.71 (1.1-7.1). In the multivariate analysis only age (positive) and FEV1% (negative) kept significant correlation with the outcome “>2 exacerbations per year” CONCLUSIONS: The use of BB in patients with heart disease is significantly lower when they also have COPD. The use of BB has a protective effect on the development of more than 2 complications per year, although this effect could be the consequence of other factors associated with the use of BB such as a better FEV1 or younger age. %U https://erj.ersjournals.com/content/erj/42/Suppl_57/3296.full.pdf